PatternsRadar
Sign in

HIKALHikal Limited

NSE
Full chart
226.43INR+11.98 (+5.59%)Close · 6 Oct 2026
6 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹2,792 CrMarket cap
—P/E (TTM)
43.8%Delivery

Filings & corporate actions

77 results filed
CSV
Next results · Q2 FY27
Expected 27 Oct 2026 – 13 Nov 2026
Estimate: filed 27–44 days after quarter end, last 5 times
Dividend
₹0.40 per share · last 4 Sept 2026
2026
  • 4 SeptdividendDividend · ₹0.40 per share-7.5%
  • 6 AugresultsResults · Q1 FY27 · consolidated and standalone+2.6%NSE
  • 20 JulshareholdingShareholding · 30 Jun 2026-0.7%NSE
  • 27 MayresultsResults · Q4 FY26 · consolidated and standalone-11.8%NSE
  • 16 AprshareholdingShareholding · 31 Mar 2026+0.4%NSE
  • 17 FebdividendDividend · ₹0.20 per share-2.5%
  • 11 FebresultsResults · Q3 FY26 · consolidated and standalone+12.8%NSE
  • 16 JanshareholdingShareholding · 31 Dec 2025-1.1%NSE

Reaction to results · all yearsrose on day 0 in 30 of 77 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY276 Aug 2026+2.6%-1.6%+0.4%1.4×
Q4 FY2627 May 2026-11.8%-14.3%-2.9%3.1×
Q3 FY2611 Feb 2026+12.8%+5.9%-9.6%131.7×
Q2 FY2613 Nov 2025-4.0%-6.4%+5.1%3.6×
Q1 FY267 Aug 2025-0.7%-12.2%-9.9%1.6×
Q4 FY2514 May 2025-6.9%-3.5%-10.0%2.5×
Q3 FY255 Feb 2025+7.1%+1.8%+6.8%2.5×
Q2 FY2512 Nov 2024+0.7%+1.7%+7.4%10.8×
Q1 FY252 Aug 2024-0.8%-5.4%-2.4%0.6×
Q4 FY249 May 2024-1.3%+4.0%+1.8%0.3×
Q3 FY249 Feb 2024-3.0%-3.2%-7.2%1.3×
Q2 FY243 Nov 2023+0.7%-0.8%+2.3%0.9×
Q1 FY248 Aug 2023-4.0%-5.3%+4.2%2.5×
Q4 FY2330 May 2023+8.7%+15.1%+12.3%31.3×
Q3 FY233 Feb 2023-6.1%-5.9%-12.7%1.1×
Q2 FY239 Nov 2022-1.5%-4.9%+12.9%1.4×
Q1 FY2311 Aug 2022+3.7%+25.5%+32.4%3.9×
Q3 FY2215 Feb 2022-0.3%-11.4%-4.2%0.3×
Q2 FY2227 Oct 2021+9.8%+5.6%+0.4%4.1×
Q1 FY225 Aug 2021+0.3%+13.5%+3.2%1.9×
Q4 FY216 May 2021-4.9%+1.0%+46.6%0.6×
Q3 FY215 Feb 2021-2.8%-7.8%-10.7%1.3×
Q2 FY214 Nov 2020+1.8%+3.8%+4.4%1.0×
Q1 FY214 Aug 2020+1.2%-0.1%+19.9%1.6×
Q4 FY2018 Jun 2020-2.0%+6.8%+5.4%1.5×
Q3 FY205 Feb 2020+1.3%-2.1%-9.9%0.6×
Q2 FY2025 Oct 2019-3.1%+3.2%-2.1%4.5×
Q1 FY202 Aug 2019+0.4%-0.1%-3.6%1.9×
Q4 FY1910 May 2019+3.3%-1.4%-1.0%1.5×
Q3 FY196 Feb 2019-0.1%+4.4%+17.1%0.4×
Q2 FY1922 Nov 2018-2.1%-2.9%+1.0%0.3×
Q1 FY1928 Aug 2018-4.7%+19.1%+11.8%3.0×
Q4 FY1818 Jun 2018+0.1%-6.1%-12.8%0.4×
Q3 FY1815 Feb 2018-0.3%-3.1%-9.2%2.6×
Q2 FY186 Nov 2017-0.3%-6.0%-6.1%0.7×
Q1 FY181 Sept 2017-0.6%+6.0%+1.7%1.1×
Q4 FY1716 Jun 2017-0.5%-1.7%-3.1%0.6×
Q3 FY173 Feb 2017+0.5%-2.7%-13.5%0.2×
Q2 FY1712 Nov 2016-2.7%-4.2%+2.1%0.9×
Q1 FY1712 Aug 2016-2.1%-10.7%-1.3%1.8×
Q4 FY169 May 2016+5.1%+6.9%+2.5%9.6×
Q3 FY164 Feb 2016-1.5%-11.6%-6.6%0.3×
Q2 FY162 Nov 2015-0.4%-6.2%+22.3%0.1×
Q1 FY1631 Jul 2015+0.9%-3.4%-14.0%1.4×
Q4 FY1511 May 2015+1.7%-1.1%-12.9%0.5×
Q3 FY152 Feb 2015-1.4%-5.9%-7.5%0.6×
Q2 FY1510 Nov 2014+1.8%+1.9%+5.8%0.7×
Q1 FY1512 Aug 2014-1.3%-4.3%+25.1%0.9×
Q4 FY1412 May 2014-2.1%-5.4%-6.2%0.8×
Q3 FY1411 Feb 2014-0.9%-3.1%+1.9%0.2×
Q2 FY148 Nov 2013+0.2%-0.4%-2.2%0.3×
Q1 FY1414 Aug 2013+0.7%-0.3%+2.4%0.6×
Q4 FY1320 May 2013-2.0%-4.2%-6.9%0.9×
Q3 FY136 Feb 2013-5.5%-13.2%-13.6%3.5×
Q2 FY136 Nov 2012-3.0%-1.1%+4.2%1.6×
Q1 FY139 Aug 2012-4.8%-4.3%+16.8%2.0×
Q4 FY1215 May 2012+0.8%+0.8%+0.3%1.7×
Q3 FY1210 Feb 2012+4.3%+1.4%+1.5%18.5×
Q2 FY1211 Nov 2011-1.9%-8.0%-10.9%1.5×
Q1 FY1228 Jul 2011-4.6%-9.1%-13.8%2.4×
Q4 FY1112 May 2011-1.9%+2.1%+2.9%1.7×
Q3 FY118 Feb 2011-8.5%-7.3%-6.0%3.3×
Q2 FY1111 Nov 2010-5.6%-12.4%-20.1%2.3×
Q1 FY1122 Jul 2010-0.5%-7.8%-0.3%0.1×
Q4 FY1030 Apr 2010-3.3%-5.9%-12.2%0.6×
Q3 FY1023 Jan 2010-5.0%-8.3%-16.9%0.6×
Q2 FY1022 Oct 2009-1.4%-9.7%-3.3%2.0×
Q1 FY1023 Jul 2009+4.1%-1.9%+8.0%1.9×
Q4 FY0930 Jun 2009+9.5%+2.0%+19.7%20.4×
Q3 FY0920 Jan 2009+2.2%-6.7%-19.3%0.4×
Q2 FY0922 Oct 2008-8.0%-14.5%-31.4%2.5×
Q1 FY0917 Jul 2008+0.5%-3.5%+1.6%0.0×
Q4 FY0828 Apr 2008+0.2%+0.6%+6.1%15.1×
Q3 FY0817 Jan 2008-1.1%-21.0%-16.4%0.2×
Q2 FY0818 Oct 2007+0.6%-2.3%-2.5%1.3×
Q1 FY0826 Jul 2007-2.6%-12.7%-15.5%1.0×
Q4 FY0725 Apr 2007-0.2%+0.1%+8.7%2.4×
Average-0.6%-2.4%-0.5%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+5.9%
Profit YoY—
Interest cost YoY—
Revenue QoQ-22.4%
Profit QoQ-151.4%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

CSV
Open215.30
Day range213.21 – 227.16
52-week range146.25 – 261.00
From 52w high-13.2%
RSI (14)53.3
ATR (14)12.03
Volume6.09L
Avg volume (20D)26.35L
Rel volume0.23×
Volatility (1Y)49.8%
Turnover₹13.8Cr
SMA 50 / 200220.03 / 206.06

Delivery percentage

Latest · 6 Oct 202643.8%
20-day avg31.6%
1-year avg43.4%
Percentile (own history)45th
Range4.3–99.9%
Sessions1,731

Over the last 20 sessions HIKAL settled 31.6% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 43.4%, so recent sessions are running 11.8 points lower than usual. The latest session ranks higher than 45% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+5.59%+8.44%-5.80%+4.15%+40.67%-11.24%

Valuation

CSV
Market cap₹2,792 Cr
P/E (TTM)—
EPS (TTM)-2.74
Shares outstanding12.35Cr
Listed14 Feb 2001

Ownership

CSV
Promoter68.85%
Promoter Δ QoQ0.00 pp
Public31.15%
FII0.99%
DII7.24%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)318.5494.3519.4402.8
YoY chg——-6.0%+5.9%
Net profit (₹ Cr)(34.9)(5.9)14.4(7.4)
YoY chg——-71.3%—
Net margin-11.0%-1.2%2.8%-1.8%
EPS-2.83-0.481.17-0.60

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 68.85% · public 31.15%
30 Jun 2021: promoter 68.77%30 Sept 2021: promoter 68.77%31 Dec 2021: promoter 68.77%31 Mar 2022: promoter 68.77%30 Jun 2022: promoter 68.77%30 Sept 2022: promoter 68.77%31 Dec 2022: promoter 68.83%31 Mar 2023: promoter 68.85%30 Jun 2023: promoter 68.85%30 Sept 2023: promoter 68.85%31 Dec 2023: promoter 68.85%31 Mar 2024: promoter 68.85%30 Jun 2024: promoter 68.85%30 Sept 2024: promoter 68.85%31 Dec 2024: promoter 68.85%31 Mar 2025: promoter 68.85%30 Jun 2025: promoter 68.85%30 Sept 2025: promoter 68.85%31 Dec 2025: promoter 68.85%31 Mar 2026: promoter 68.85%30 Jun 2026: promoter 68.85%
2021-062026-06
  • Promoter
  • Public and others
Promoter
68.85%
Public
31.15%
Promoter change
0.00 pp
Filed
20 Jul 2026
FII
0.99%
DII
7.24%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations434.9447.6514.1406.8452.9447.7552.4380.4318.5494.3519.4402.8
Other income1.00.10.50.50.43.60.51.01.92.86.61.8
Total income435.9447.6514.6407.3453.3451.3552.9381.4320.4497.1526.0404.6
Total expenses419.0426.0467.2400.4428.5427.5484.6411.8367.4468.3470.6423.4
└ Finance costs13.114.215.319.818.818.717.917.114.915.514.614.9
└ Depreciation28.629.032.331.831.733.237.739.441.241.242.042.7
Profit before tax16.921.647.36.924.823.868.3(30.4)(47.0)(9.2)8.3(9.9)
Tax expense4.35.513.41.86.56.618.1(8.0)(12.1)(3.3)(6.1)(2.5)
Net profit12.616.134.05.118.317.250.2(22.4)(34.9)(5.9)14.4(7.4)
EPS1.021.312.760.411.481.394.07-1.82-2.83-0.481.17-0.60
Net margin2.89%3.61%6.61%1.25%4.04%3.84%9.09%-5.89%-10.96%-1.19%2.77%-1.84%
PBT margin3.88%4.83%9.20%1.70%5.48%5.32%12.36%-7.99%-14.76%-1.86%1.60%-2.46%
Tax rate25.44%25.31%28.21%26.09%26.21%27.73%26.50%———-73.49%—

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 6 Aug 2026.

HIKAL at a glance

  • HIKAL closed at ₹226.43 on 6 Oct 2026, +5.59% on the day, -11.2% over one year, 13.2% below its 52-week high of ₹261.
  • Delivery was 43.8% of traded quantity on 6 Oct 2026, the 45th percentile of its own 1,731 sessions with a reading (20-session average 31.6%, 1-year average 43.4%).
  • Market capitalisation is ₹2,792 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-2.74).
  • Q1 FY27 results (consolidated, filed 6 Aug 2026): revenue ₹403 crore (+5.9% year on year), net profit ₹-7 crore; the price moved +2.6% on the first session after.
  • Promoters held 68.85% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 27 Oct 2026 and 13 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE475B01022
SeriesEQ
Listed14 Feb 2001
History from14 Feb 2001
Sessions6,220
Turnover rank#412

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE